Jazz Pharmaceuticals grants 1,605 RSUs to director
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Kennedy Patrick reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals director Patrick Kennedy reported a grant of 1,605 restricted stock units, each representing one ordinary share, under the company’s 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Subject to continuous service and conditions, the units vest in full on July 23, 2027, bringing his direct holdings to 8,307 ordinary shares.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Ordinary Shares F1 | 1,605 | $0.00 | $0.00 |
Footnotes (1)
- F1. These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 23, 2027.
Key Figures
Key Terms
restricted stock units financial
contingent right financial
continuous service financial
Non-Employee Directors Stock Award Plan financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Patrick Kennedy report for Jazz Pharmaceuticals (JAZZ)?
What are the vesting terms of Patrick Kennedy’s new Jazz (JAZZ) restricted stock units?
Under which plan were Patrick Kennedy’s Jazz (JAZZ) restricted stock units granted?
AI-generated analysis. How Rhea-AI works. Not financial advice.